News | EP Lab

May 15, 2019 — A new infection risk scoring system has been developed based on data from the large PADIT Trial.[1] The ...

Home May 15, 2019
Home
News | Atrial Fibrillation | Dave Fornell, Editor

May 15, 2019 — Renal artery denervation (RDN) was found to be safe when employed with pulmonary vein isolation (PVI) to ...

Home May 15, 2019
Home
News | EP Lab

May 15, 2019 - Three new studies show that patients who are medically indicated for implantable heart devices, including ...

Home May 15, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT) | Dave Fornell, Editor

May 15, 2019 — A pilot trial has shown His pacing in cardiac resynchronization therapy (CRT) has been shown to ...

Home May 15, 2019
Home
HRS 2019 late breaking trials, late breaking presentations for the biggest news in electrophysiology (EP). #HRS #HRS2019 #HRS19
Feature | HRS | Dave Fornell, Editor

May 15, 2019 — The Heart Rhythm Society (HRS) had 21 late-breaking study presentations at the 2019 Heart Rhythm ...

Home May 15, 2019
Home
Technology | Ventricular Assist Devices (VAD)

The U.S. Food and Drug Administration (FDA) has approved the expansion of Abiomed’s Impella 5.0 and Impella LD premarket approval (PMA) labeling for the treatment of cardiogenic shock. The expansion extends the duration of support for each pump from 6 days to 14 days.

Home May 14, 2019
Home
News | Atrial Fibrillation | Dave Fornell, Editor

May 14, 2019 – The first prospective, multicenter, randomized, controlled trial to compare conventional pulmonary vein ...

Home May 14, 2019
Home
News

The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus statement reflecting a worldwide updated review of the indications, techniques and outcomes of catheter ablation of ventricular arrhythmias (VAs). The expert consensus statement was presented at Heart Rhythm 2019, the HRS’s 40th Annual Scientific Sessions, May 8-11 in San Francisco.

Home May 14, 2019
Home
News | Cardiac Diagnostics

The Heart Rhythm Society (HRS) released a first-of-its-kind consensus statement with guidance on the evaluation and management of arrhythmogenic cardiomyopathy (ACM), including findings on genetics and disease mechanisms. Recommendations included in the 2019 HRS Expert Consensus Statement on Evaluation, Risk Stratification, and Management of Arrhythmogenic Cardiomyopathy were presented at Heart Rhythm 2019, the HRS’s 40th Annual Scientific Sessions, May 8-11 in San Francisco.

Home May 14, 2019
Home
News | EP Lab

May 14, 2019 – Results from new research show that passengers with cardiac implantable electronic devices (CIEDs), such ...

Home May 14, 2019
Home
News | Implantable Cardioverter Defibrillator (ICD)

May 13, 2019 — Boston Scientific announced acute results from the UNTOUCHED study evaluating safety and efficacy of the ...

Home May 13, 2019
Home
News | EP Lab

May 13, 2019 – Results from a new survey are the first to report a large discrepancy in patient’s knowledge of their ...

Home May 13, 2019
Home
News

May 13, 2019 – A first-in-human pilot study of Medtronic's investigational Extravascular Implantable Cardioverter ...

Home May 13, 2019
Home
News | Atrial Fibrillation

May 13, 2019 — A randomized clinical trial effectively used nerve stimulation through an ear clip to reduce atrial ...

Home May 13, 2019
Home
News | Atrial Fibrillation

May 13, 2019 — A digital screening for atrial fibrillation (AFib or AF) successfully monitored more than 60,000 ...

Home May 13, 2019
Home
Subscribe Now